Physician profile
Roberto Arce
NPI 1396747127
$7,107.46
in general payments reported to CMS, 2019-2025
35 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $627 · 2021: $737 · 2022: $1,208 · 2023: $960 · 2024: $1,818 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.02 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $749.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $607.78 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $594.80 | 2019-2025 | Farxiga, Wainua |
| Medtronic Vascular, INC. | $514.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $494.81 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $475.84 | 2022-2025 | |
| Medtronic, INC. | $362.94 | 2022-2025 | Corevalve Evolut R, Sprint Quattro Secure S Mri Surescan |
| Impulse Dynamics (USA) INC. | $341.42 | 2022-2025 | Optimizer, Optimizer |
| Amgen INC. | $320.88 | 2019-2024 | Repatha |
| Abbott Laboratories | $310.85 | 2021-2024 | Gallant |
| Janssen Pharmaceuticals, INC | $285.47 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $245.37 | 2021-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.19 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $194.00 | 2019-2025 | Watchman Flx, Spyglass |
| Amarin Pharma, INC. | $189.93 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $148.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $140.58 | 2021-2024 | Onpattro |
| Esperion Therapeutics, INC. | $129.95 | 2020-2021 | |
| Cleerly, INC. | $85.99 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Merck Sharp & Dohme LLC | $84.14 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $75.82 | 2019-2023 | |
| Lilly USA, LLC | $54.84 | 2024-2025 | Zepbound, Mounjaro |
| Lexicon Pharmaceuticals, INC. | $45.14 | 2023-2024 | Inpefa |
| Azurity Pharmaceuticals, INC. | $45.00 | 2023-2024 | Edarbi, Edarbi |
| Kiniksa Pharmaceuticals International, Plc | $44.56 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $43.31 | 2025 | Attruby |
| Scpharmaceuticals INC. | $41.71 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $41.22 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $35.80 | 2019 | |
| Akcea Therapeutics, INC. | $34.10 | 2020 | |
| Glaxosmithkline, LLC. | $32.68 | 2025 | Arexvy, Shingrix |
| Kestra Medical Technology Services, INC. | $30.40 | 2025 | Assure Wcd |
| Atricure, INC. | $24.70 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2023 | Jardiance |
| Aegerion Pharmaceuticals, INC. | $18.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Arce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.